¾Æµå¹Ýźũ¸²(¸ÞÆ¿ÇÁ·¹µå´Ï¼Ö·Ð¾Æ¼¼Æ÷³×ÀÌÆ®) 15g  ADVANTAN CREAM  
                    
                 
               
              
                
                     Àü¹®ÀǾàǰ | »èÁ¦   
                        
                    	
                    
                 
               
              
                
					  
                  
				  
                 
               
              
              
              
              
                 
              
                
                    
                       
                      ¾Ë¸²:  
                      µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. 
                     
                  
 
               
            
              
                
                   
                   
                   
                   
		   
                 
               
              
                
                  
                     
                    
                       Àü¹®/ÀÏ¹Ý 
		              
                    Àü¹®
                       
                      
                        
                        
                          
                            
                                
                             
                           
                           
                           
                          
                          Èò»ö ³»Áö ´©¸£½º¸§ÇÑ »öÀ» ¶ì´Â Å©¸²  
                          
                           
                          
			              
                            
                            
							  
							 
                             
                           
                          
                          
                            
                              
                               
                             
                           
                          
                          
                            
                            
							 
                             
                           
                          
                        
                        
                       
                     
                    
                      
					   Á¦Á¶È¸»ç 
                      
                       
                        ¹ÙÀÌ¿¤ÄÚ¸®¾Æ(ÁÖ) 
                      
                       
                     
                    
                      
					   ÆÇ¸Åȸ»ç 
                      
                       
			            ¹ÙÀÌ¿¤ÄÚ¸®¾Æ(ÁÖ) 
                      
                       
                     
                      
                      
                      
					   Çã°¡Á¤º¸ 
                      
                      
                                          Á¤»ó                   
                                          
                          
                                (2006.11.24) 
                           
                            
                       
                     
                    
                     
                        
	    				   BIT ¾àÈ¿ºÐ·ù 
                        
                          ¿Ü¿ë ½ºÅ×·ÎÀ̵å (Steroids : Skin & Mucous Membrane)
                         
                     
                    
                    
                      
					   º¹ÁöºÎºÐ·ù 
                      264[ÁøÅ롤Áø¾ç¡¤¼ö·Å¡¤¼Ò¿°Á¦                                        ] 
                     
                    
                      
					   û±¸ÄÚµå(KDÄÚµå)    ºñ±Þ¿©Á¡°ËÄÚµå 
                      
                      
                      
                        
641105961  \0 ¿ø/15g/°³(2021.02.01) (ÇöÀç¾à°¡) \2,409 ¿ø/15g/°³(2020.01.01) (º¯°æÀü¾à°¡) 
                         
                        
						     
						     
                         
                      
                     
                       
                     
                     
                    
                       ATCÄÚµå 
                      Methylprednisolone aceponate  / D07AC14 
                     
                    
                    
                       NDCÄÚµå 
                      
                        [Proprietary Name Search _ ƯÇãµî·Ï¸í,»óÇ¥¸íÀ¸·Î °Ë»ö]  
                        [Active Ingredient Search _ ÁÖ¼ººÐÀ¸·Î °Ë»ö]  
                        [NDC Number Search _ NDCÄÚµå·Î °Ë»ö]  
                       
                                         
                    
                      
					   ¼ººÐ / ÇÔ·®  
                      
			
			
			[½ÉÆò¿ø ÁÖ¼ººÐÄÚµå ±âÁØ ¼ººÐÇÔ·®Á¤º¸ Á¶È¸]   
			
			 
					                            
                       
                     
                        
                      
                      
					   ÷°¡Á¦ 
                      
                      
                           °æÁúÁö¹æ ,
                          
                           ±Û¸®¼¼·Ñ¸ð³ë½ºÅ׾Ʒ¹ÀÌÆ®40-55 ,
                          
                           ±Û¸®¼¼¸°85% ,
                          
                           µðºÎÆ¿È÷µå·Ï½ÃÅç·ç¿£ ,
                          
                           ¸¶Å©·Î°ñ½ºÅ׾Ʒ¹ÀÌÆ® ,
                          
                           º¥Áú¾ËÄÚ¿Ã ,
                          
                           ¼¼Å佺Å׾Ƹ±¾ËÄÚ¿Ã ,
                          
                           ¼ÙƼÀÜ378 ,
                          
                           ¿¡µ¥Æ®»ê³ªÆ®·ý ,
                          
                           ¿Ã·¹»êµ¥½Ç ,
                          
                          Á¤Á¦¼ö 
                                          
                       
                     
                  
                  
                 
               
            
 
            
         
      
       
   
   
  
    
      
     
     
  
                              
                                  
                                   
                               
            
            
                
            
            
              
            
                            
              
                                                     
            
            
   
  
    
      
     
   
   
     
   
    
   
    
      
        À¯·áȸ¿ø °áÀç½Ã ¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸ ¸¦
        ÀÌ¿ë ÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
        À¯·áÁ¤º¸¸ñ·Ï Àº Àü¹®È¸¿ø À¸·Î
        ·Î±×ÀÎ  ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
      
     
   
  
     
   
   
  
    
      
	
	  
	     
	    
	      
	        
            
              Çã°¡Á¤º¸ 
                         
	        
	       
	     
	     
	    
  
    Ç׸ñ 
    ³»¿ë 
   
  
   
    û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå  »óÇÑ±Ý¾× 
    
      
      
        
        641105961  
	    
	    
          [º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]   
          
        
        
        
          
          
            \0 ¿ø/15g/°³(2021.02.01) (ÇöÀç¾à°¡)  
            \2,409 ¿ø/15g/°³(2020.01.01)(º¯°æÀü¾à°¡) 
        
          
            
	 
  	   
  	   
       
      
       
       
     
      
      
     
      
    
    
      
     [»óº´ÄÚµåÁ¶È¸]  
      
     [Áúº´ÄÚµåÁý ´Ù¿î·Îµå]  
     [¿ì¸®Áý°Ç°ÁÖÄ¡ÀÇ ¹Ù·Î°¡±â]  
     
   
   
    ºü¸¥Á¶È¸ 
    
      
       
   
  
  
   
    Á¦Ç°¼º»ó 
    
      Èò»ö ³»Áö ´©¸£½º¸§ÇÑ »öÀ» ¶ì´Â Å©¸²  
      
	    [Á¦ÇüÁ¤º¸ È®ÀÎ]  
       
   
  
  
  
  
  
   
    Æ÷À塤À¯Åë´ÜÀ§ 
    15±×·¥/Æ©ºê 
   
  
  
  
  
  	
   
    ÁÖ¼ººÐÄÚµå 
    
      193433CCM  
      
	  [µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]  
     
   
  
  
  
  
  	
   
    ´ëÇ¥ÄÚµå 
    8806411059604 
   
  
  
  
  
   
    º¸°ü¹æ¹ý 
    25¡É ÀÌÇÏ ±â¹Ð¿ë±â 
   
  
  
  
   
    ¾à¸®ÀÛ¿ë 
    
      
        [Á¶È¸]  
     
      
  
  
  
  
   
    È¿´ÉÈ¿°ú 
     
    [ÀûÀÀÁõ º° °Ë»ö]   
      
    
     
	 
       ½ÀÁø(¾ÆÅäÇÇÇǺο°, ½É»ó¼º½ÀÁø µî)
      
      
      
      
     
   
  
  
  
  
  
  
  
  
    
  
  
   
    ¿ë¹ý¿ë·® 
     
      * Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.  
    
     
      
      
    [󹿾à¾î]  
       1ÀÏ 1ȸ Àû´ç·®À» ȯºÎ¿¡ ¾ã°Ô ¹Ù¸¥´Ù. ¼ºÀÎÀÇ °æ¿ì 12ÁÖ, ¼Ò¾ÆÀÇ °æ¿ì´Â 4ÁÖ ÀÌ»ó °è¼ÓÇØ¼ »ç¿ëÇÏÁö ¾Ê´Â´Ù.      
      	    
     
   
  
  
  
  
  
  
  
  
  
   
    ±Ý±â 
     
       1) ¼¼±Õ(°áÇÙ, ¸Åµ¶ µî)․Áø±Õ(ĵð´ÙÁõ, ¹é¼± µî)․¹ÙÀÌ·¯½º(´ë»óÆ÷Áø, ´Ü¼øÆ÷Áø, ¼öµÎ, Á¾µÎÁõ µî)․¹é½ÅÁ¢Á¾ÈÄÀÇ ÇǺÎÁúȯ․µ¿¹°(¿È, »ç¸é¹ßÀÌ µî)¼º ÇǺΰ¨¿°Áõ ȯÀÚ(Áõ»óÀÌ ¾Ç鵃 ¼ö ÀÖ´Ù) 
 2) ÀÌ ¾à ¶Ç´Â ÀÌ ¾à ¼ººÐ¿¡ °ú¹ÎÁõ ¹× ±× º´·ÂÀÌ Àִ ȯÀÚ 
 3) °í¸· õ°øÀÌ ÀÖ´Â ½ÀÁø¼º ¿ÜÀ̵µ¿° ȯÀÚ(õ°øºÎÀ§ÀÇ Ä¡À¯Áö¿¬ÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù) 
 4) ±Ë¾ç(º£Ã¼Æ®º´ Á¦¿Ü), Á¦2µµ ½ÉÀ缺 ÀÌ»óÀÇ È»ó․µ¿»ó ȯÀÚ(ÇǺÎÀç»ýÀÌ ¾ïÁ¦µÇ¾î Ä¡À¯°¡ Áö¿¬µÉ ¼ö ÀÖ´Ù) 
 5) ÀÔÁÖÀ§ÇǺο°, º¸Åë¿©µå¸§, ÁÖ»ç ȯÀÚ 
 6) 3¼¼ ÀÌÇÏÀÇ À¯¾Æ
     
   
  
  
  
  
   
    ½ÅÁßÅõ¿© 
     1) ÀӺΠ¶Ç´Â ÀÓ½ÅÇϰí ÀÖÀ» °¡´É¼ºÀÌ ÀÖ´Â ºÎÀÎ ¹× ¼öÀ¯ºÎ  
2) À¯¡¤¼Ò¾Æ  
3) °í·ÉÀÚ  
 
   
  
  
  
   
    ÀÌ»ó¹ÝÀÀ 
     
      1) ÇǺΠ
  ¨ç °¨¿°Áõ : ÇǺÎÀÇ ¼¼±Õ¼º(Àü¿°¼º ³ó°¡Áø, ¸ð³¶¿° µî) ¹× Áø±Õ¼º(ĵð´ÙÁõ, ¹é¼± µî) °¨¿°ÁõÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù[¹ÐºÀºØ´ë¹ý(ODT)ÀÇ °æ¿ì ³ªÅ¸³ª±â ½±´Ù]. ÀÌ¿Í °°Àº Áõ»óÀÌ ³ªÅ¸³¯ °æ¿ì¿¡´Â ÀûÀýÇÑ Ç×±ÕÁ¦³ª Ç×Áø±ÕÁ¦ µîÀ» º´¿ëÇÏ°í ½Å¼ÓÈ÷ °³¼±µÇÁö ¾ÊÀ» °æ¿ì¿¡´Â »ç¿ëÀ» ÁßÁöÇÑ´Ù. 
  ¨è ÀϹÝÀû ÇǺÎÁõ»ó : ¸ð³¶¿°, ºÎ½º·³, ÇǺÎÀÚ±Ø, ÀÚÅë, ¹ß¿, ÀÛ¿°¨, ¹ßÁø, ¹ßÀû, È«Á¶, °¡·Á¿ò, ÇǺΰÇÁ¶, ³óÆ÷¼ºÇǺο°, ¾Ë·¹¸£±â¼º Á¢ÃËÇǺο°, ¶¡¶ì, ÇÑÁø, »óó¾ÇÈ, ¿åâ, ³óÆ÷Áõ µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¸ç, ÀÌ·¯ÇÑ Áõ»óÀÌ ³ªÅ¸³¯ °æ¿ì¿¡´Â »ç¿ëÀ» ÁßÁöÇÑ´Ù.
  ¨é Àå±â ¿¬¿ë : ½ºÅ×·ÎÀ̵强 ¿©µå¸§, ½ºÅ×·ÎÀ̵强 ÇǺÎ(ÇǺÎÀ§Ãà, ¸ð¼¼Ç÷°üÈ®Àå, ÀÚ¹Ý), ½ºÅ×·ÎÀ̵强 ÁÖ»ç, ÀÔÁÖÀ§ÇǺο°(ÀÔÁÖÀ§․¾È¸éÀüü¿¡ È«¹Ý, ±¸Áø, ¸ð¼¼Ç÷°üÈ®Àå, µüÁö, Àμ³), ¾î¸°¼±(åà×÷àÐ)¾ç ÇǺκ¯È, ´Ù¸ð, ÇǺκ¯»ö, ¼±Á¶, ¼öÆ÷¼ºÇǺο°, ¾ÆÅäÇÇÇǺο°, ÇǺÎÃâÇ÷ µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. ÀÌ·¯ÇÑ Áõ»óÀÌ ³ªÅ¸³¯ °æ¿ì¿¡´Â õõÈ÷ »ç¿ë·®À» ÁÙ¿© ÄÚ¸£Æ¼ÄÚÀ̵带 ÇÔÀ¯ÇÏÁö ¾ÊÀº ¾àÀ¸·Î ¹Ù²Ù¾î »ç¿ëÇÑ´Ù.
 2) ³»ºÐºñ°è : ´ë·® ¶Ç´Â Àå±â°£¿¡ °ÉÄ£ ±¤¹üÀ§ÇÑ »ç¿ë, ¹ÐºÀºØ´ë¹ý¿¡ ÀÇÇØ ÄÚ¸£Æ¼ÄÚÀ̵å Àü½Å Åõ¿©¿Í °°Àº ³úÇϼöü․ºÎ½ÅÇÇÁú°è ±â´ÉÀÇ ¾ïÁ¦¸¦ °¡Á®¿Ã ¼ö ÀÖÀ¸¹Ç·Î ÁÖÀÇÇÑ´Ù.
 3) ´« : ¾È°ËÇǺο¡ »ç¿ë½Ã ¾È¾Ð »ó½Â, ³ì³»ÀåÀ» ÀÏÀ¸Å³ ¼ö ÀÖÀ¸¹Ç·Î ÁÖÀÇÇÑ´Ù. ´ë·® ¶Ç´Â Àå±â°£¿¡ °ÉÄ£ ±¤¹üÀ§ÇÑ »ç¿ë, ƯÈ÷ ¹ÐºÀºØ´ë¹ýÀ» »ç¿ëÇÒ °æ¿ì Èij¶ÇϹ鳻Àå, ³ì³»Àå µîÀ̳ªÅ¸³¯ ¼ö ÀÖ´Ù.
          
     
   
  
  
    
   
    ÀϹÝÀû ÁÖÀÇ 
    1) ÇǺΠ°¨¿°À» ¼ö¹ÝÇÏ´Â ½ÀÁø․ÇǺο°¿¡´Â »ç¿ëÇÏÁö ¾Ê´Â °ÍÀ» ¿øÄ¢À¸·Î ÇÏÁö¸¸ ºÎµæÀÌÇÏ°Ô ÀÌ ¾àÀ» »ç¿ëÇÏ´Â °æ¿ì¿¡´Â ¸ÕÀú ÀûÀýÇÑ Ç×±ÕÁ¦, Ç×Áø±ÕÁ¦·Î Ä¡·áÇϰųª À̵é°úÀÇ º´¿ëÀ» °í·ÁÇÑ´Ù.
 2) ±¹¼Ò ÄÚ¸£Æ¼ÄÚÀ̵åÀÇ Àü½ÅÀû Èí¼ö´Â ¸î¸î ȯÀÚ¿¡¼ °¡¿ªÀûÀÎ ½Ã»óÇϺÎ-³úÇϼöü-ºÎ½Å(HPA) ÃàÀÇ ¾ïÁ¦, Äí½ÌÁõÈıº, °úÇ÷´çÁõ, ´ç´¢ µîÀ» ÀÏÀ¸Å³ ¼ö ÀÖÀ¸¹Ç·Î ±¹¼Ò ÄÚ¸£Æ¼ÄÚÀ̵带 ±¤¹üÀ§ÇÑ Ã¼Ç¥¸é ¶Ç´Â ¹ÐºÀºØ´ë¹ý ÇÏ¿¡ »ç¿ëÇϴ ȯÀÚ´Â Á¤±âÀûÀ¸·Î Ç÷Áß ÄÚ¸£Æ¼¼Ö ³óµµ, ¿äÁß¿¡ À¯¸®µÇ´Â ÄÚ¸£Æ¼¼ÖÀ» ÃøÁ¤Çϰųª ACTH ÀڱؽÃÇèÀ» ÇÏ¿© HPAÃà ¾ïÁ¦¸¦ °Ë»çÇÑ´Ù.
 3) ±¹¼Ò ÄÚ¸£Æ¼ÄÚÀ̵åÀÇ Àü½ÅÀû Èí¼ö·Î ÀÎÇØ HPAÃàÀÌ ¾ïÁ¦µÇ¾ú´Ù¸é ¾à¹°»ç¿ëÀÇ ÁßÁö, Åõ¿©ºóµµÀÇ °¨¼Ò, Ȱ¼ºÀÌ ¾àÇÑ ÄÚ¸£Æ¼ÄÚÀ̵å·ÎÀÇ ´ëü µîÀÇ ¹æ¹ýÀ» ½ÃµµÇϰí ÀϹÝÀûÀ¸·Î ±¹¼Ò ÄÚ¸£Æ¼ÄÚÀÌµå ¾à¹°Åõ¿© ÁßÁö ÈÄ HPA Ãà ±â´ÉÀº ½Å¼ÓÈ÷ ȸº¹µÈ´Ù.
 4) Áõ»óÀÌ °³¼±µÇÁö ¾Ê°Å³ª ¾ÇȵǴ °æ¿ì¿¡´Â »ç¿ëÀ» ÁßÁöÇÑ´Ù.
 5) Áõ»óÀÌ °³¼±µÇ¸é °¡´ÉÇÑ ÇÑ ºü¸¥ ½ÃÀÏ ³»¿¡ »ç¿ëÀ» ÁßÁöÇÑ´Ù.
 6) ³ÐÀº ºÎÀ§¿¡ ÀÌ ¾àÀ» »ç¿ë½Ã ´Ü±â°£(7ÀÏ ÀÌÇÏ) »ç¿ëÇÑ´Ù.
 7) ÄÚ¸£Æ¼ÄÚÀÌµå ±¹¼ÒÁ¦Á¦ÀÇ ³ÐÀº üǥ¸é¿¡ ´ëÇÑ ±¤¹üÀ§ÇÑ »ç¿ë ¶Ç´Â Àå±â°£ÀÇ »ç¿ëÀº ÀÌ»ó¹ÝÀÀÀÇ À§ÇèÀ» À¯ÀÇÀûÀ¸·Î Áõ°¡½ÃŲ´Ù(ƯÈ÷ ¹ÐºÀ »ç¿ë½Ã). 
   
  
  
  
  
  
  
   
    ÀӺο¡ ´ëÇÑ Åõ¿© 
     
      
	[ÀӺαݱ⠼ººÐ Á¶È¸]         
      ÀӺο¡ ´ëÇÑ ¾ÈÀü¼ºÀÌ È®¸³µÇ¾î ÀÖÁö ¾ÊÀ¸¹Ç·Î ÀӺΠ¶Ç´Â ÀÓ½ÅÇϰí ÀÖÀ» °¡´É¼ºÀÌ ÀÖ´Â ºÎÀο¡ ´ëÇØ¼´Â ´ë·® ¶Ç´Â Àå±â°£(3ÁÖ ÀÌ»ó)¿¡ °ÉÄ£ ±¤¹üÀ§ÇÑ »ç¿ëÀ» ÇÇÇϰí Ä¡·á»óÀÇ À¯ÀͼºÀÌ À§Ç輺À» »óȸÇÑ´Ù°í ÆÇ´ÜµÉ °æ¿ì¿¡¸¸ Åõ¿©ÇÑ´Ù.
     
   
  
  
  
  
   
    ¼öÀ¯ºÎ¿¡ ´ëÇÑ Åõ¿© 
     1) ÀÌ ¾àÀÌ ¸ðÀ¯ ÁßÀ¸·Î ÀÌÇàÇÑ´Ù´Â º¸°í´Â ¾øÀ¸³ª ¼öÀ¯ºÎ¿¡ Åõ¿©½Ã ÁÖÀÇÇÑ´Ù. 
 2) ¼öÀ¯½Ã °¡½¿ºÎÀ§¿¡ ÀÌ ¾àÀ» »ç¿ëÇÏÁö ¾Ê´Â´Ù. 
   
  
  
  
  
   
    ¼Ò¾Æ¿¡ ´ëÇÑ Åõ¿© 
     
      
       
       1) ¼Ò¾Æ´Â üÁß´ç üǥ¸éÀûÀÇ ºñÀ²ÀÌ ¼ºÀκ¸´Ù Ä¿¼ ÄÚ¸£Æ¼ÄÚÀ̵å·Î ÀÎÇØ HPAÃà ¾ïÁ¦, Äí½ÌÁõÈıº, ¹ßÀ°Àå¾Ö µîÀÌ ³ªÅ¸³ª±â ½¬¿ì¹Ç·Î ÁÖÀÇÇÑ´Ù. 
 2) ±âÀú±Í µîÀº ¹ÐºÀºØ´ë¹ý°ú °°Àº ÀÛ¿ëÀ» ³ªÅ¸³¾ ¼ö ÀÖÀ¸¹Ç·Î ÁÖÀÇÇÑ´Ù. 
   
  
  
  
   
    °í·ÉÀÚ¿¡ ´ëÇÑ Åõ¿© 
     
      ÀϹÝÀûÀ¸·Î °í·ÉÀÚ¿¡¼´Â ÀÌ»ó¹ÝÀÀÀÌ ³ªÅ¸³ª±â ½¬¿ì¹Ç·Î ´ë·®, Àå±â°£, ±¤¹üÀ§ÇϰÔ(ƯÈ÷ ¹ÐºÀºØ´ë¹ý) »ç¿ëÇÒ °æ¿ì ÃæºÐÈ÷ °üÂûÇÏ´Â µî ÁÖÀÇÇÑ´Ù.
 
   
  
  
  
  
  
  
  
  
  
    
   
    Àû¿ë»óÀÇ ÁÖÀÇ 
      1) ¾È°ú¿ëÀ¸·Î »ç¿ëÇÏÁö ¾Ê´Â´Ù. 
 2) ÈÀåÀ̳ª ¸éµµ ÈÄ µî Ä¡·á ÀÌ¿ÜÀÇ ¸ñÀûÀ¸·Î »ç¿ëÇÏÁö ¾Ê´Â´Ù. 
 3) ÀÇ»çÀÇ °¨µ¶ ¾øÀÌ ¹ÐºÀºØ´ë¹ýÀ» »ç¿ëÇÏÁö ¾Ê´Â´Ù(ƯÈ÷ ¹ÐºÀºØ´ë¹ýÀ» »ç¿ëÇÒ °æ¿ì ¼¼±Õ °¨¿°ÀÌ ³ªÅ¸³ª±â ½¬¿ì¹Ç·Î Àû¿ëÀü¿¡ ȯºÎ¸¦ û°áÈ÷ ÇÑ´Ù). 
   
  
  
  
  
  
  		
  
  
   
    º¸°ü ¹× Ãë±Þ»óÀÇ ÁÖÀÇ 
        ¾î¸°ÀÌÀÇ ¼ÕÀÌ ´êÁö ¾Ê´Â °÷¿¡ º¸°üÇÑ´Ù. 
   
  	
  
  
  
  
  
  
  
      							
 
	  
	 
	
	  
       
	    
	      
	        
            
              Á¤º¸¿ä¾à 
                 
	        
	       
	           	    
	     
	    
  
    µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸ 
    
  
  
    
  
    
	  
	 
	
	  
       
	    
	      
	        
            
              ÄÚµå ¹× ºÐ·ùÁ¤º¸ 
                 
	        
	       
	           	    
	     
	    	  
	  
	 
	
	  
       
	    
	      
	        
            
              Á¦Ç°Á¤º¸ 
                             
	        
	       
	           	  
	     
	     
	  
	 
	
	  
       
	    
	      
	        
            
              º¹¾àÁ¤º¸ 
                             
	        
	       
	           	  
	     
	    
  
    Ç׸ñ 
    ³»¿ë 
   
   
    LACTmed ¹Ù·Î°¡±â 
    
      
        [¹Ù·Î°¡±â]  
     
     
  
  
   
    ¾à¸®ÀÛ¿ë 
    
       
      À¯·áÁ¤º¸ÀÔ´Ï´Ù. 
       
     
     
  
  
  
   
    Ãà¾àº¹¾àÁöµµ 
    
     
    À¯·áÁ¤º¸ÀÔ´Ï´Ù. 
    
     
   
       
  
  
   
    º¹¾àÁöµµ 
    
     
    À¯·áÁ¤º¸ÀÔ´Ï´Ù. 
    
     
   
                                                          															
  
   
  
  
   
    ÀӺο¡´ëÇÑÅõ¿© 
    
      
      
        
	      
	      
	        *   
	        
	          ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù. 
	          
	         
	      
	       
	   
	  
	      
	   
	  
	    
	     FDA : Cµî±Þ 
				        	
					  
					
	   
	  
	  
	  
	     
	     
	     
	     
	     
	     
	   
	 
	
	  
	      
	      
	        *   
	        
	          »ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. 
	         
	         
	      
	        *   
	        
	          ¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í  ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù. 
	         
	         
	      
	   
	 
      
     
   
  
  
  	   
  
  	   
  
  	   
  
  
     
      Pharmacokinetics 
      
       
      À¯·áÁ¤º¸ÀÔ´Ï´Ù. 
      
         
     
  
  
  
  
  
  
  	
  
  
  	
  
  
   
    Á¦Çüº° º¹¾àÁöµµ 
    [Å©¸²]  
   
  
  
   
    º¸°ü»ó ÁÖÀÇ 
    
      
    	
     
   
  
  
   
    Á¶Á¦½Ã ÁÖÀÇ 
    
      
    	
     
      
 
	  
	 
	
	  
       
	    
	      
	        
            
              ½É»çÁ¤º¸ 
                             
	        
	       
	           	  
	     
	     
	  
	   
	
	  
       
	    
	      
	        
            
              ÇмúÁ¤º¸ 
                             
	        
	       
	           	  
	     
	    
  
    Ç׸ñ 
    ³»¿ë 
   
  
    DUR (ÀǾàǰ»ç¿ëÆò°¡) 
    º´¿ë±Ý±â :
     
	 °í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
	 
	 [»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]  										
	  ¿¬·É´ë±Ý±â :
      °í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
      
      [¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]  
       
       
        
        
     
   
  
   
    Mechanism of Action 
    
      MethylPrednisolone¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸  Unbound glucocorticoids cross cell membranes and bind with high affinity to specific cytoplasmic receptors, modifying transcription and protein synthesis. By this mechanism, glucocorticoids can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. 
     
   
  
   
    Pharmacology 
     
      MethylPrednisolone¿¡ ´ëÇÑ Pharmacology Á¤º¸  Methylprednisolone and its derivatives, methylprednisolone sodium succinate and methylprednisolone acetate, are synthetic glucocorticoids used as antiinflammatory or immunosuppressive agents. 
     
   
  
   
    Metabolism 
    
      MethylPrednisolone¿¡ ´ëÇÑ Metabolism Á¤º¸  # Phase_1_Metabolizing_Enzyme:Cytochrome P450 3A4 (CYP3A4) 
     
   
  
   
    Protein Binding 
    
      MethylPrednisolone¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸  78% 
     
   
  
   
    Half-life 
    
      MethylPrednisolone¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸  1-3 hours 
     
   
  
   
    Absorption 
    
      MethylPrednisolone¿¡ ´ëÇÑ Absorption Á¤º¸  Oral bioavailability 80-99% 
     
   
  
   
    Pharmacokinetics 
    
      MethylPrednisolone aceponateÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á  
	ÃÖ´ëÈ¿°ú  ¹ßÇö½Ã°£°ú È¿°úÁö¼Ó½Ã°£Àº Åõ¿©°æ·Î¿¡ µû¶ó ´Ù¸¥´Ù.
	 
	 
	 ºÐÆ÷: Vd : 0.7L/kg
	 ¹Ý°¨±â : 3¡3.5½Ã°£
	Methylprednisolone sodium succinate´Â ¹°¿¡ ´ëÇÑ ¿ëÇØ¼ºÀÌ ¸Å¿ì Å©±â ¶§¹®¿¡ Á¤¸ÆÁֻ糪 ±ÙÀ°Áֻ縦 ÇÏ´Â °æ¿ì È¿°ú°¡ ºü¸£°Ô ³ªÅ¸³´Ù; Methylprednisolone acetate´Â ¿ëÇØ¼ºÀÌ ³·±â ¶§¹®¿¡ ±ÙÀ°ÁÖ»ç½Ã Áö¼ÓÀûÀÎ È¿°ú¸¦ ³ªÅ¸³½´Ù.  
  
     
   
  
   
    Biotransformation 
    
      MethylPrednisolone¿¡ ´ëÇÑ Biotransformation Á¤º¸  Hepatic 
     
   
  
   
    Toxicity 
    
      MethylPrednisolone¿¡ ´ëÇÑ Toxicity Á¤º¸  LD50 =2000 mg/kg (orally in rat) 
     
   
  
   
    Drug Interactions 
    
      MethylPrednisolone¿¡ ´ëÇÑ Drug_Interactions Á¤º¸  Not Available 
     
   
  
   
    CYP450  Drug Interaction 
    
      [CYP450 TableÁ÷Á¢Á¶È¸]  
     
   
  
   
    Drug Target 
    
      
      [Drug Target]  
     
   
  
   
    Description 
    
      MethylPrednisolone¿¡ ´ëÇÑ Description Á¤º¸  A prednisolone derivative with similar anti-inflammatory action. [PubChem] 
     
   
  
   
    Dosage Form 
    
      MethylPrednisolone¿¡ ´ëÇÑ Dosage_Form Á¤º¸  Powder	IntramuscularPowder	IntravenousPowder, for solution	IntravenousSuspension	IntramuscularTablet	Oral 
     
   
  
   
    Drug Category 
    
      MethylPrednisolone¿¡ ´ëÇÑ Drug_Category Á¤º¸  Adrenergic AgentsAnti-inflammatory AgentsAntiemeticsGlucocorticoidsNeuroprotective Agents 
     
   
  
   
    Smiles String Canonical 
    
      MethylPrednisolone¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸  CC1CC2C3CCC(O)(C(=O)CO)C3(C)CC(O)C2C2(C)C=CC(=O)C=C12 
     
   
  
   
    Smiles String Isomeric 
    
      MethylPrednisolone¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸  C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12 
     
   
  
   
    InChI Identifier 
    
      MethylPrednisolone¿¡ ´ëÇÑ InChI_Identifier Á¤º¸  InChI=1/C22H30O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,9,12,14-15,17,19,23,25,27H,5,7-8,10-11H2,1-3H3/t12-,14-,15-,17-,19+,20-,21-,22-/m0/s1 
     
   
  
   
    Chemical IUPAC Name 
    
      MethylPrednisolone¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸  (6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one 
     
   
  
   
    Drug-Induced Toxicity Related Proteins 
    
      METHYLPREDNISOLONE   ÀÇ Drug-Induced Toxicity Related ProteinÁ¤º¸Replated Protein  :Tyrosine aminotransferaseDrug  :methylprednisolone Toxicity  :liver toxicity. [¹Ù·Î°¡±â] Replated Protein  :P-selectin Drug  :methylprednisolone Toxicity  :chronic idiopathic thrombocytopenic purpura (ITP). [¹Ù·Î°¡±â] Replated Protein  :Interleukin-6 Drug  :methylprednisolone Toxicity  :chronic idiopathic thrombocytopenic purpura (ITP). [¹Ù·Î°¡±â] Replated Protein  :Glucocorticoid receptorDrug  :methylprednisolone Toxicity  :liver toxicity. [¹Ù·Î°¡±â] Replated Protein  :Thrombopoietin (TPO)Drug  :methylprednisolone  Toxicity  :chronic idiopathic thrombocytopenic purpura (ITP). [¹Ù·Î°¡±â] METHYLPREDNISOLONE (MPL)   ÀÇ Drug-Induced Toxicity Related ProteinÁ¤º¸Replated Protein  :Glucocorticoid receptorDrug  :methylprednisolone (MPL) Toxicity  :liver toxicity. [¹Ù·Î°¡±â] Replated Protein  :Tyrosine aminotransferaseDrug  :methylprednisolone (MPL) Toxicity  :liver toxicity. [¹Ù·Î°¡±â] PREDNISOLONE   ÀÇ Drug-Induced Toxicity Related ProteinÁ¤º¸Replated Protein  :DNA topoisomerase 1Drug  :prednisolone Toxicity  :appearance of apoptotic cells. [¹Ù·Î°¡±â]  
     
   
    
 
	  
	   
	
	  
       
	    
	      
	        
            
              »ç¿ëÀÚÄÁÅÙÃ÷ 
                             
	        
	       
	           	  
       
	     
	  
	     	
 
  
   
   
     
   
  
    
      
        
          
            
              
                ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2024-07-25
               
              
                
                º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
                 
                   
             
                         
      
           
          
                
                    
                       ¾Ë¸² 
                       
                      »ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù.  
                    
                  
 
               
      
      
                
                    
                       °æ°í 
                     
                      µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù. 
                          Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â 
                          Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡± ¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
                            ¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù. 
                          ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
 
                    
                  
 
               
  
  
    ¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é 
    ¿©±â ·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
  
  
 
  º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ